AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ - Contacts and Locations

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

This study has been terminated.

Study NCT00058747. Last updated on April 19, 2006. Information provided by Antigenics

Please refer to this study by its ClinicalTrials.gov identifier: NCT00058747

Locations


United States, Alabama

	Birmingham, Alabama, United States

United States, California

	Los Angeles, California, United States

	La Jolla, California, United States

United States, Colorado

	Denver, Colorado, United States

United States, Connecticut

	Farmington, Connecticut, United States

United States, Illinois

	Chicago, Illinois, United States

United States, Massachusetts

	Boston, Massachusetts, United States

United States, Missouri

	St. Louis, Missouri, United States

United States, New York

	New York City, New York, United States

United States, Oregon

	Portland, Oregon, United States

United States, Pennsylvania

	Pittsburgh, Pennsylvania, United States

United Kingdom

	London, United Kingdom

	Liverpool, United Kingdom

Sponsors and Collaborators

Antigenics